Hansa Biopharma AB(HNSA)

Description: Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

---

Keywords: Cancer Biopharmaceutical Antibodies Autoimmune Disease Immunotherapy Gene Therapy Antibody Transplantation Muscular Dystrophy Dystrophy Treatment Of Autoimmune Disease Duchenne Muscular Dystrophy Kidney Transplant Duchenne Sarepta Therapeutics Pompe Disease Imlifidase Limb Girdle Muscular Dystrophy Limb–Girdle Muscular Dystrophy

---

Home Page: www.hansabiopharma.com

ScheelevAegen 22
Lund, 223 63
Sweden
Phone: 46 46 16 56 70

---

Officers

Exchange: ST

Country: SE : Sweden

Currency: Swedish krone (kr)